Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
Jesper Damsgaard Gunst, Nina Breinholt Stærke, Marie H. Pahus, et al.
EClinicalMedicine (2021) Vol. 35, pp. 100849-100849
Open Access | Times Cited: 173

Showing 1-25 of 173 citing articles:

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
Tirosh Shapira, I. Abrrey Monreal, Sébastien P. Dion, et al.
Nature (2022) Vol. 605, Iss. 7909, pp. 340-348
Open Access | Times Cited: 181
How the coronavirus infects cells — and why Delta is so dangerous
Megan Scudellari
Nature (2021) Vol. 595, Iss. 7869, pp. 640-644
Closed Access | Times Cited: 161
Acute and chronic neurological disorders in COVID-19: potential mechanisms of disease
Erin F. Balcom, Avindra Nath, Christopher Power
Brain (2021) Vol. 144, Iss. 12, pp. 3576-3588
Open Access | Times Cited: 141
Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity
Rachid Essalmani, Jaspreet Jain, Delia Susan‐Resiga, et al.
Journal of Virology (2022) Vol. 96, Iss. 8
Open Access | Times Cited: 135
Cardiovascular disease and COVID-19: a consensus paper from the ESC Working Group on Coronary Pathophysiology & Microcirculation, ESC Working Group on Thrombosis and the Association for Acute CardioVascular Care (ACVC), in collaboration with the European Heart Rhythm Association (EHRA)
Edina Cenko, Lina Badimón, Raffaele Bugiardini, et al.
Cardiovascular Research (2021) Vol. 117, Iss. 14, pp. 2705-2729
Open Access | Times Cited: 131
Sexual dimorphism in COVID-19: potential clinical and public health implications
Nicole Bechmann, Andreas Barthel, Andreas Schedl, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 3, pp. 221-230
Open Access | Times Cited: 106
TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS‐CoV‐2 infection
Renée M. van der Sluis, Lamin B. Cham, Albert Gris‐Oliver, et al.
The EMBO Journal (2022) Vol. 41, Iss. 10
Open Access | Times Cited: 78
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 74
Therapeutics for COVID-19
Sima S. Toussi, Jennifer Hammond, Brian S. Gerstenberger, et al.
Nature Microbiology (2023) Vol. 8, Iss. 5, pp. 771-786
Open Access | Times Cited: 73
TMPRSS2 Is Essential for SARS-CoV-2 Beta and Omicron Infection
Kristin Metzdorf, Henning Jacobsen, Marina C. Greweling‐Pils, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 271-271
Open Access | Times Cited: 47
Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets
Masoumeh Farahani, Zahra Niknam, Leila Mohammadi Amirabad, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112420-112420
Open Access | Times Cited: 103
COVID‐19 and ischemic stroke
Dimitrios Sagris, Aikaterini Papanikolaou, Alexandra Kvernland, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 11, pp. 3826-3836
Open Access | Times Cited: 85
An update of anti-viral treatment of COVID-19
Serap Şimşek Yavuz, İpek Komşuoğlu Çelikyurt
TURKISH JOURNAL OF MEDICAL SCIENCES (2021) Vol. 51, Iss. SI-1, pp. 3372-3390
Open Access | Times Cited: 78
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment
Lukas Wettstein, Frank Kirchhoff, Jan Münch
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1351-1351
Open Access | Times Cited: 57
SARS-CoV-2 Antiviral Therapy
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Clinical Microbiology Reviews (2021) Vol. 34, Iss. 4
Open Access | Times Cited: 57
A common TMPRSS2 variant has a protective effect against severe COVID-19
Alessia David, Nick Parkinson, Thomas P. Peacock, et al.
Current Research in Translational Medicine (2022) Vol. 70, Iss. 2, pp. 103333-103333
Open Access | Times Cited: 47
Altered host protease determinants for SARS-CoV-2 Omicron
Jasper Fuk‐Woo Chan, Xiner Huang, Bingjie Hu, et al.
Science Advances (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 32
SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
Anna Z. Mykytyn, Tim I. Breugem, Maarten H. Geurts, et al.
Journal of Virology (2023) Vol. 97, Iss. 8
Open Access | Times Cited: 28
Computational screening combined with well-tempered metadynamics simulations identifies potential TMPRSS2 inhibitors
C. S. Sharanya, D. Sasikala Wilbee, Shijulal Nelson‐Sathi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 9
Common Variable Immunodeficiency Disorders, T-Cell Responses to SARS-CoV-2 Vaccines, and the Risk of Chronic COVID-19
Rohan Ameratunga, Hilary Longhurst, Richard Steele, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 9, Iss. 10, pp. 3575-3583
Open Access | Times Cited: 48
Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein
Mizuki Yamamoto, Jin Gohda, Ayako Kobayashi, et al.
mBio (2022) Vol. 13, Iss. 4
Open Access | Times Cited: 38
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 36
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective
J. Carlos Menéndez
Molecules (2022) Vol. 27, Iss. 3, pp. 658-658
Open Access | Times Cited: 32
Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?
Xing Chang, Nur Izzah Ismail, Attaur Rahman, et al.
Antioxidants and Redox Signaling (2022)
Open Access | Times Cited: 31
Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19
Francisco Javier Redondo Calvo, Juan Fernando Padín, José Ramón Muñoz‐Rodríguez, et al.
European Journal of Clinical Investigation (2022) Vol. 52, Iss. 6
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top